ARS Pharmaceuticals, Inc. (SPRY) Institutional Ownership

Ownership Summary

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) has 184 institutional investors with active 13F positions as of December 2025.

• Collectively, these holders controlled 92.3% of ARS Pharmaceuticals's outstanding shares in December 2025, up from 84.8% in September 2025.
• Their total shares held in SPRY increased 15.7% from the prior quarter, while the number of investors in ARS Pharmaceuticals increased 12.88% year over year.
• During the quarter, 90 of these 184 funds increased positions in SPRY, 55 reduced exposure, and 39 held steady.
• In total, institutional investors held 91.17Mn shares in ARS Pharmaceuticals as of December 2025, up by 12.38Mn shares quarter on quarter, and up 17.91Mn shares year over year.
• RA CAPITAL MANAGEMENT, L.P. holds the largest position in SPRY at 10.86Mn shares as of December 31, 2025, or 10.99% of shares outstanding.
• The biggest buyers of ARS Pharmaceuticals for the quarter ending December 2025 included Tyro Capital Management LLC (3.99Mn), MILLENNIUM MANAGEMENT LLC (3.17Mn), Rubric Capital Management LP (1.7Mn), UBS Group AG (1.55Mn), FIL Ltd (810.07K).
• Leading sellers of ARS Pharmaceuticals shares for the quarter ending December 2025 were ALLIANCEBERNSTEIN L.P. (2.58Mn), Eversept Partners, LP (724.92K), Goldman Sachs Group Inc (513.7K), Trexquant Investment LP (481.62K), FMR LLC (343.55K).
• Per Business Quant, the top 10 investors in SPRY for the quarter ending December 2025 include RA CAPITAL MANAGEMENT, L.P. (10.86Mn), ORBIMED ADVISORS LLC (8.29Mn), DEERFIELD MANAGEMENT COMPANY, L.P. (7.5Mn), Rubric Capital Management LP (6.2Mn), BlackRock, Inc. (5.09Mn), SR ONE CAPITAL MANAGEMENT, LP (4.01Mn), Tyro Capital Management LLC (3.99Mn), Aberdeen Group plc (3.56Mn), VANGUARD GROUP INC (3.51Mn), State Street Corp (3.22Mn).